Rakuten Medical, Inc., a clinical-stage, global biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy (PIT) platform, has raised approximately US $100 million on July 31, 2019, in a Series C-1 Preferred Stock financing from Rakuten, Inc., a global leader in internet services headquartered in Japan. This investment is increasing Rakuten’s equity share of Rakuten Medical to 22.6 percent.
Rakuten Medical Releases Phase 2a Study Data during ASCO Annual Meeting Highlighting Positive Safety Profile and Clinically Meaningful Anti-tumor Activity
Clinically meaningful activity of RM-1929 Photoimmunotherapy in patients with locoregional, recurrent head and neck cancer Generally well-tolerated treatment results and an overall response rate of 43 percent (95 percent CI 25.5-62.6) Initiates Phase 3…
Rakuten Medical Opens two new Offices in the Netherlands and Taiwan, Adding new Jobs to Strengthen and Expand its Global Presence
New office in Amsterdam will be the second location in Europe for Rakuten Medical; Taipei is the second office in Asia Additional hires across the globe will support the company’s accelerated growth within biotechnology…
Rakuten Medical Highlights Upcoming Presentations and Activities During the ASCO Annual Meeting, May 31 – June 4, 2019 in Chicago
Rakuten Medical, a clinical-stage biotechnology company developing precision-targeted cancer therapies based on its proprietary photoimmunotherapy (PIT) platform, will be presenting data from its Phase 2a clinical trial focused on RM-1929 PIT in patients with locoregional, recurrent…
Rakuten Medical’s ASP-1929 photoimmunotherapy for head and neck cancers to be designated under the Sakigake Designation System for its potential innovativeness and effectiveness
San Mateo, April 8, 2019 – Based on its exclusive license related to photoimmunotherapy, Rakuten Medical Inc., which is developing a cancer therapy to target cancer cells, announced that ASP-1929 received Sakigake designation under…
